Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.
作者信息
Marks Suzanne M, Dowdy David W, Menzies Nicolas A, Shete Priya B, Salomon Joshua A, Parriott Andrea, Shrestha Sourya, Flood Jennifer, Hill Andrew N
机构信息
1242 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
1466 Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
出版信息
Public Health Rep. 2020 Jul/Aug;135(1_suppl):38S-43S. doi: 10.1177/0033354920912710.
Abstract
摘要
相似文献
1
Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.加速结核病消除的潜伏性结核感染检测与治疗策略数学模型的政策影响
Public Health Rep. 2020 Jul/Aug;135(1_suppl):38S-43S. doi: 10.1177/0033354920912710.
2
Screening for Latent Tuberculosis Infection: A Key Step Toward Achieving Tuberculosis Elimination in the United States.潜伏性结核感染筛查：美国实现消除结核病的关键一步。
JAMA Intern Med. 2016 Oct 1;176(10):1439-1440. doi: 10.1001/jamainternmed.2016.5464.
3
SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.SIRCLE：自我给药的短程异烟肼和利福喷汀用于具有成本效益的潜伏性结核根除的随机对照成本比较
Intern Med J. 2017 Dec;47(12):1433-1436. doi: 10.1111/imj.13601.
4
Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.在模拟模型中，针对有和无合并症的出生于美国境外的居民，检测和治疗潜伏性结核病感染的成本效益。
JAMA Intern Med. 2017 Dec 1;177(12):1755-1764. doi: 10.1001/jamainternmed.2017.3941.
5
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.迈向消除结核病。结核病感染诊断与治疗研究的关键问题。
Am J Respir Crit Care Med. 2019 Mar 1;199(5):564-571. doi: 10.1164/rccm.201806-1053PP.
6
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?治疗潜伏性结核感染的成本效益：迈向消除结核病的一步？
Int J Tuberc Lung Dis. 2013 Dec;17(12):1515. doi: 10.5588/ijtld.13.0706.
7
Tuberculosis.结核病。
Nurs Clin North Am. 2019 Jun;54(2):193-205. doi: 10.1016/j.cnur.2019.02.008. Epub 2019 Mar 28.
8
Practice guideline for treatment of latent tuberculosis infection in children.儿童潜伏性结核感染治疗实践指南。
J Pediatr Health Care. 2015 May-Jun;29(3):302-7. doi: 10.1016/j.pedhc.2015.02.002. Epub 2015 Mar 17.
9
The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.欧盟/欧洲经济区移民中潜伏性结核病筛查的效果和成本效益：系统评价。
Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00543.
10
Modeling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low-Incidence Setting.在低发病地区对近期移民进行潜伏性结核病筛查和治疗策略的成本效果建模。
Am J Epidemiol. 2022 Jan 24;191(2):255-270. doi: 10.1093/aje/kwab150.
引用本文的文献
1
Inclusion of non-medical interventions in model-based economic evaluations for tuberculosis: A scoping review.纳入基于模型的结核病经济评估中的非医学干预措施：范围综述。
PLoS One. 2023 Aug 25;18(8):e0290710. doi: 10.1371/journal.pone.0290710. eCollection 2023.
2
Trends in tuberculosis clinicians' adoption of short-course regimens for latent tuberculosis infection.结核病临床医生采用短程疗法治疗潜伏性结核感染的趋势。
J Clin Tuberc Other Mycobact Dis. 2023 Jun 13;33:100382. doi: 10.1016/j.jctube.2023.100382. eCollection 2023 Dec.
3
Policy and Public Health : Reducing the Burden of Infectious Diseases.政策与公共卫生：减轻传染病负担
Public Health Rep. 2020 Jul/Aug;135(1_suppl):5S-9S. doi: 10.1177/0033354920932641.
本文引用的文献
1
Modeling the Impact of Recommendations for Primary Care-Based Screening for Latent Tuberculosis Infection in California.模拟加利福尼亚州基于初级保健的潜伏性结核感染筛查建议的影响
Public Health Rep. 2020 Jul/Aug;135(1_suppl):172S-181S. doi: 10.1177/0033354920927845.
2
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.潜伏结核感染治疗指南：美国国家结核病控制协会和美国疾病预防控制中心 2020 年推荐意见。
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
3
Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.加利福尼亚州结核病流行病学和政策结果的比较建模。
Am J Respir Crit Care Med. 2020 Feb 1;201(3):356-365. doi: 10.1164/rccm.201907-1289OC.
4
Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis.加利福尼亚州、佛罗里达州、纽约州和德克萨斯州州级结核病干预措施的影响和效果：基于模型的分析。
Am J Epidemiol. 2019 Sep 1;188(9):1733-1741. doi: 10.1093/aje/kwz147.
5
Outlook for tuberculosis elimination in California: An individual-based stochastic model.加利福尼亚州消除结核病的前景：基于个体的随机模型。
PLoS One. 2019 Apr 9;14(4):e0214532. doi: 10.1371/journal.pone.0214532. eCollection 2019.
6
Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015.2011-2015 年加利福尼亚、佛罗里达、纽约和得克萨斯州高危人群中的结核病发病率。
Am J Public Health. 2018 Nov;108(S4):S311-S314. doi: 10.2105/AJPH.2018.304503.
7
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.成人潜伏性结核：利福平治疗 4 个月或异烟肼治疗 9 个月。
N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.
8
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.异烟肼-利福平每周方案治疗潜伏性结核分枝杆菌感染的推荐更新。
MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-726. doi: 10.15585/mmwr.mm6725a5.
9
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.美国消除结核病的前景：传播动力学模型的结果。
Am J Epidemiol. 2018 Sep 1;187(9):2011-2020. doi: 10.1093/aje/kwy094.
10
Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities.美国的结核病死亡率：流行病学与预防机遇
Ann Am Thorac Soc. 2018 Jun;15(6):683-692. doi: 10.1513/AnnalsATS.201705-405OC.
Zotero 插件